English
This article is from Indian Journal of Pharmacology , volume 44 . Abstract Background:: Superficial fungal infections are common and treatment imposes economic burden on the patients. Government of India had introduced price control over griseofulvin and tolnaftate in 1995; however, this measure can only benefit the needy if the policy is harmonized with the health-care service provider, that is, dermatologists. The aim of this study was to evaluate the existing Government mechanisms over price control of antifungal medications and its reach to the people-in-need. Materials and Methods:: A questionnaire-based, cross-sectional study was carried out over a period of 6 months. Questionnaire was mailed to members of a state branch of Indian Association of Dermatologists, Venereologists, and Leprologists. Responses reaching investigators within 2 months from the date of mailing were finally analyzed. Results:: Among 93 (41.33%) respondents, only 6 (6.5%) were aware of existing price control over griseofulvin but none about tolnaftate. Thirty-nine (41.9%) respondents were in favor of introducing price control on terbinafine and 42 (45.2%) for itraconazole. The topically preferred antifun
Sign in with your free account to read, download EPUBs or listen.
Ebook · A study to evaluate the price control of antifungal medicines and its practical applicability. · Sil, Amrita, Das, Nilay Kanti, Ghosh, Pramit, Datta, Pijush Kanti, Islam, Chowdhury Nazrul, Tripathi, Santanu Kumar · Internet Archive